Third generation oral contraceptive use and cardiovascular risk factors

被引:23
作者
Döring, A
Fröhlich, M
Löwel, H
Koenig, W
机构
[1] Univ Ulm, Med Klin, Med Ctr, Dept Internal Med 2, D-89081 Ulm, Germany
[2] GSF Res, Natl Res Ctr Environm & Hlth, Inst Epidemiol, D-85764 Neuherberg, Germany
[3] Univ Heidelberg Hosp, Dept Internal Med 6, Heidelberg, Germany
关键词
oral contraceptives; population-based sample; epidemiology; third generation OC pills; lipids; markers of systemic inflammation;
D O I
10.1016/j.atherosclerosis.2003.10.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To analyze the relationship between third generation oral contraceptive (OC) use and various cardiovascular risk factors-including markers of inflammation-in a population-based sample. Study population and methods: Data on OC use were obtained from women, aged 25-44 years participating in the MONICA Augsburg survey 1994-1995. Complete data were available from 841 women. Third generation OCs were defined as OCs containing desogestrel or gestodene, the remaining OC products were summarized in the group "other OC." Results: Women taking third generation OCs had significantly higher C-reactive protein, fibrinogen, plasma viscosity, and HDL-cholesterol concentrations compared to the "other OC" group and non-users. In contrast, LDL-cholesterol was identical in the three groups. The analyses of interaction between smoking and OC use revealed that smoking women taking third generation pills had a less favourable pattern concerning inflammatory markers compared to women not on OC or using other products. Conclusion: Potentially harmful effects of OCs may arise from their positive association with the acute phase response. There is a close relationship with inflammatory markers in particular in women taking third generation OCs, which may, at least in part, contribute to the increased atherothrombotic risk, reported specifically in these women. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:281 / 286
页数:6
相关论文
共 27 条
[1]  
[Anonymous], 1998, CVD Prevention
[2]   Epidemiology of oral contraceptives and cardiovascular disease [J].
Chasan-Taber, L ;
Stampfer, MJ .
ANNALS OF INTERNAL MEDICINE, 1998, 128 (06) :467-477
[3]   Prospective study of oral contraceptives and hypertension among women in the United States [J].
ChasanTaber, L ;
Willett, WC ;
Manson, JE ;
Spiegelman, D ;
Hunter, DJ ;
Curhan, G ;
Colditz, GA ;
Stampfer, MJ .
CIRCULATION, 1996, 94 (03) :483-489
[4]   Safety evaluation of modern oral contraceptives -: Effects on lipoprotein and carbohydrate metabolism [J].
Crook, D ;
Godsland, I .
CONTRACEPTION, 1998, 57 (03) :189-201
[5]   Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses [J].
Danesh, J ;
Whincup, P ;
Walker, M ;
Lennon, L ;
Thomson, A ;
Appleby, P ;
Gallimore, JR ;
Pepys, MB .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7255) :199-204
[6]   Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease - Meta-analyses of prospective studies [J].
Danesh, J ;
Collins, R ;
Appleby, P ;
Peto, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (18) :1477-1482
[7]   Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women [J].
Decensi, A ;
Omodei, U ;
Robertson, C ;
Bonanni, B ;
Guerrieri-Gonzaga, A ;
Ramazzotto, F ;
Johansson, H ;
Mora, S ;
Sandri, MT ;
Cazzaniga, M ;
Franchi, M ;
Pecorelli, S .
CIRCULATION, 2002, 106 (10) :1224-1228
[8]   Oral contraceptives and myocardial infarction: results of the MICA case-control study [J].
Dunn, N ;
Thorogood, M ;
Faragher, B ;
de Caestecker, L ;
MacDonald, TM ;
McCollum, C ;
Thomas, S ;
Mann, R .
BRITISH MEDICAL JOURNAL, 1999, 318 (7198) :1579-1583
[9]   Metabolic interrelationships, cardiovascular disease, and sex steroids [J].
Fotherby, K .
CONTRACEPTION, 1998, 57 (03) :183-187
[10]   Oral contraceptive use is associated with a systemic acute phase response [J].
Fröhlich, M ;
Döring, A ;
Imhof, A ;
Hutchinson, WL ;
Pepys, MB ;
Koenig, W .
FIBRINOLYSIS & PROTEOLYSIS, 1999, 13 (06) :239-244